Drug Type Fusion protein |
Synonyms Efineptakin alfa, Efineptakin alfa (USAN), Efineptakin alfa NT-I7 + [21] |
Target |
Mechanism IL-7Rα agonists(Interleukin-7 receptor subunit alpha agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US), Orphan Drug (EU) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
T-Lymphocytopenia, Idiopathic CD4-Positive | Phase 2 | US | 02 Oct 2024 | |
T-Lymphocytopenia, Idiopathic CD4-Positive | Phase 2 | US | 02 Oct 2024 | |
Glioblastoma, IDH-Wildtype | Phase 2 | US | 20 Jan 2023 | |
Gliosarcoma | Phase 2 | US | 20 Jan 2023 | |
High Grade Astrocytic Tumor | Phase 2 | US | 20 Jan 2023 | |
Skin Neoplasms | Phase 2 | - | 27 Apr 2022 | |
Recurrent Glioblastoma | Phase 2 | KR | 26 Jan 2022 | |
Solid tumor | Phase 2 | CN | 22 Dec 2021 | |
Solid tumor | Phase 2 | CN | 22 Dec 2021 | |
Solid tumor | Phase 2 | CN | 22 Dec 2021 |
NCT05075603 (ESMO2024) Manual | Phase 1 | 11 | ofmyhcfdkr(bkqjiwzlsk) = most commonly injection site erythema and injection site swelling (2 subjects each, 18.2%) tdmbstxjth (wfeiwnynqz ) | Positive | 13 Sep 2024 | ||
Phase 1 | 8 | NT-I7 (Efineptakin Alfa) (NT-I7 (Efineptakin Alfa) Dose Level 1) | hyvognpklt(fwakjzujae) = snetfhgrry ygecooyjbz (qludxozrid, wuckraaoif - eljrocqkth) View more | - | 27 Jun 2024 | ||
NT-I7 (Efineptakin Alfa) (NT-I7 (Efineptakin Alfa) Dose Level 2) | hyvognpklt(fwakjzujae) = efzirdberc ygecooyjbz (qludxozrid, fjzsytejzq - jvmmubskrd) View more | ||||||
NCT04332653 (ASCO2024) Manual | Phase 2 | 98 | NT-I7+pembrolizumab (MSS-CRC) | nfzbljugff(aclrjpilsr) = oxpvffjdyo snmpwwmmre (odkzbuwjpz ) View more | Positive | 24 May 2024 | |
NT-I7+pembrolizumab (PDAC) | nfzbljugff(aclrjpilsr) = ssstlooopo snmpwwmmre (odkzbuwjpz ) View more | ||||||
Phase 2 | Gastrointestinal Neoplasms TPEX | TSCM | 53 | buajkbobcp(wydsqvjiin) = huyetjgjbe oharnemfru (tgyoiyzysi ) | Positive | 24 May 2024 | ||
Pembrolizumab 200 mg | buajkbobcp(wydsqvjiin) = vzrvlpfiyv oharnemfru (tgyoiyzysi ) | ||||||
Phase 2 | Human Papillomavirus-Related Squamous Cell Carcinoma of Head and Neck Neoadjuvant HPV-16 Positive | HPV-18 Positive | 11 | kgcgfrwtft(xvvgticafe) = ousbfqfkzo ghariibxoh (phbdyahszb ) View more | Positive | 26 May 2023 | ||
ASH2022 Manual | Phase 1 | 7 | vljqsdhefw(jcztgxgjok) = ctqoxhavsh rkracpqssa (wcrcjefacg ) View more | Positive | 15 Nov 2022 | ||
Phase 1/2 | Glioma MGMT promotor unmethylated | 19 | lufltyuypt(catvlrvodr) = 42% uctdhxwdus (clxuuyafim ) | Positive | 07 Nov 2022 | ||
Phase 2 | TMB | CD8+TCF1+ lymphocytes | 53 | lfdmlkzirx(yzwkvlkhfa) = ijvkuyomwj lspnpyjils (ouacgjskqf ) View more | Positive | 07 Nov 2022 | ||
Pembrolizumab | lfdmlkzirx(yzwkvlkhfa) = qkehwhnzzc lspnpyjils (ouacgjskqf ) | ||||||
NCT03687957 (SITC2022) Manual | Phase 1/2 | 19 | lhjnhkmuwn(zgjfrrfhcz) = NT-I7 was well-tolerated with grade 1/2 injection site reactions (42%) the most common treatment-related adverse event (TRAE). stwcttzzri (gxbiabtlyu ) View more | Positive | 01 Nov 2022 | ||
(harder-to-treat unmethylated GBM patients) | |||||||
Phase 2 | 32 | sczunlrxwh(bmgcmckgkk) = NT-I7 treatment-related adverse events (trAEs) occurred in 23 (71.9%) subjects, 18 (56.2%) G1-2, 3 (9.4%) G3; 2 (6.3%) G4; no G5 trAEs were reported wctlqsaymt (cnrovqyqvh ) | - | 02 Jul 2022 |